FDA Approval: ENLICITIDE (ENLICITIDE CHLORIDE) — Type 1 - New Molecular Entity
FDA-NDA220848 · Multi-specialty
Enlicitide approved; billing pathway pending FDA label publication.
View alertCode intelligence
Policy changes, MAC LCD updates, and CMS guidance matched to code S09.
No policy changes are currently matched to S09
CMS, MAC, and Federal Register sources are monitored daily. When a policy change is matched to this code, it will appear here automatically.
Latest reimbursement alerts
The most recent policy changes across all codes and specialties.
FDA-NDA220848 · Multi-specialty
Enlicitide approved; billing pathway pending FDA label publication.
View alertFDA-NDA218879 · Neurology
Oral lamotrigine suspension routes to Part D; formulary impact likely.
View alertLCD-DL33317 · DME
Proposed LCD: External breast prostheses coverage criteria open for comment.
View alertLCD-DL33797 · DME
Proposed DME MAC LCD may revise oxygen coverage & documentation rules.
View alertLCD-L35074 · Clinical Laboratory
Final LCD restricts Medicare coverage for heavy metal lab testing.
View alertLCD-L37606 · Oncology
Genomic panel coverage criteria for blood/lymphoid cancers—Part A & B.
View alertLCD-L37475 · ESRD
Wellpoint final LCD sets coverage rules for hemodialysis frequency.
View alertLCD-L33399 · Neurology
Wellpoint Final LCD: Ambulatory EEG coverage criteria effective 4/1/2026
View alertAudit documentation
The Tripwire Audit Pack exports 12 months of single-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.